1. Scrip
  2. >>Business

New Hope, Funding Approaches As Roche Brings Evrysdi To India

Zolgensma Provided In India Through Managed Access Program

 
• By Anju Ghangurde

Roche’s Evrysdi debuts in India backed by a patient support program ahead of Novartis’ Zolgensma and Biogen’s Spinraza. Spotlights remains on the price tag for the SMA therapy amid hopes that novel approaches such as crowdfunding could also broaden access.

Roche bldg
Evrysdi Is Now Available In India • Source: Alamy

Roche has brought Evrysdi (risdiplam) to India ahead of rival spinal muscular atrophy (SMA) treatments Novartis AG’ Zolgensma (onasemnogene abeparvovec) and Biogen, Inc.’s Spinraza (nusinersen), backed by a patient support program (PSP) that could potentially soften the pricing blow for patients in a largely out-of-pocket market.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Zelluna Believes Its TCR Tech Can Unlock Natural Killer Cell Potential

 
• By Andrew McConaghie

While CAR-NKs have pivoted towards autoimmune disease, the Norwegian biotech believes its unique platform can deliver in oncology

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.